NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Affordable Growth Candidate

Affordable growth stocks combine solid financial health, strong profitability, and reasonable valuations with consistent earnings and revenue expansion. These companies often outperform peers while trading at attractive prices relative to their growth potential. One such candidate is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a global healthcare leader specializing in diabetes and obesity care.

Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Fits the Affordable Growth Criteria

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) scores an 8 out of 10 in ChartMill’s fundamental rating, indicating strong performance across key financial metrics. Here’s why it stands out:

Strong Growth Prospects

With a Growth rating of 7, NVO demonstrates solid expansion. Revenue grew 25.03% over the past year, while earnings per share (EPS) increased 21.57%. Analysts project continued growth, with EPS expected to rise 13.97% annually.

Outstanding Profitability

The company earns a Profitability rating of 9, reflecting industry-leading margins. Its Return on Assets (21.68%) and Return on Equity (70.38%) rank in the top percentile of pharmaceutical peers. Operating margins stand at 46.16%, reinforcing efficient operations.

Solid Financial Health

NVO holds a Health rating of 7, supported by manageable debt levels and strong cash flow. Its Altman-Z score of 5.46 suggests low bankruptcy risk, and the debt-to-free-cash-flow ratio of 1.48 indicates quick repayment capacity.

Attractive Valuation

Despite strong fundamentals, NVO trades at a Valuation rating of 7, with a P/E ratio of 19.21, below the S&P 500 average (28.88). Its Price/Forward Earnings of 16.05 is also favorable compared to industry peers.

For a deeper analysis, review the full fundamental report on NVO.

Finding Similar Stocks

Investors looking for more affordable growth stocks can explore this predefined screen.

Conclusion

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) presents a compelling case as an affordable growth stock, balancing strong financials, profitability, and reasonable valuation. While past performance is impressive, future growth expectations further support its investment case.